Trial reportFrontiers in medicine2025
Efficacy and safety of intradermal botulinum toxin A for post-acne erythema: a split-face randomized controlled trial.
Trial report in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exploring the Therapeutic Potential of Botulinum Toxin in Treating Post-Acne Sequelae: A Critical Review.Clinical, cosmetic and investigational dermatology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Post-acne erythema (PAE) is a common aesthetic sequela in patients with acne. Although numerous treatments for PAE have been investigated, the efficacy of intradermal botulinum toxin A (BTX-A) remains controversial. This study aimed to evaluate and compare the efficacy and safety of intradermal BTX-A versus broadband light (BBL) for treating PAE. Materials and methods: This study included 30 patients diagnosed with PAE at the Dermatology Outpatient Department of Henan Provincial People's Hospital in China between January 2023 and July 2023. In a split-face design, one cheek of each patient was randomly assigned to receive a single intradermal injection of BTX-A (experimental group), while the other cheek received three BBL treatments at one-month intervals (control group). The Clinician Erythema Assessment (CEA) score, VISIA results, L*a*b* values, skin physiological parameters, and adverse events were compared between the two groups. Results: The two groups showed no significant differences in baseline characteristics. At the one-month follow-up, the experimental group demonstrated significantly greater reduction in CEA, erythema index (EI), a* value, and sebum secretion compared to the control group ( Conclusion: In this split-face study, a single session of intradermal BTX-A was superior to a multi-session BBL regimen in reducing PAE over three months, with a comparable safety profile. These findings suggest that intradermal BTX-A is a promising and viable therapeutic option for PAE, warranting further investigation in larger, long-term studies. Clinical trial registration: The trial was registered before patient enrolment at http://www.chictr.org.cn (ChiCTR2500098527).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.